基于的药物作为从Lytechinus variegatus脊柱的动脉样硬化多目标疗法:一个in silico研究
Dessy Arisanty1,2, Salsabila P Khairani2, Kevin N Cuandra3
1Department of Biochemistry, Faculty of Medicine, Universitas Andalas, Padang, Indonesia.
Narra J
|September 15, 2025
概括
来自Lytechinus variegatus棘的9显示出作为动脉样硬化的一种非有毒的多目标抑制剂的前景. 这种新有效地向关键蛋白质,提供潜在的治疗益处,药物相互作用风险最小.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 动脉样硬化是一种主要的心血管疾病,由动脉斑块积累引起.
- 需要新的治疗策略来有效地对抗这种疾病.
研究的目的:
- 研究来自Lytechinus variegatus棘的酸作为潜在的动脉样硬化治疗药物.
- 用in silico方法评估的安全性,药理动力学特性和结合亲和力.
主要方法:
- 选择了与动脉样硬化相关的关键蛋白质:VEGFR,AKT1,EGFR,MAPK8和ET-1.
- 进行了包括毒性,ADME预测和分子对接在内的分析.
- 评估的结合亲和度 (kcal/mol) 和根平均平方偏差 (RMSD) (Å).
主要成果:
- 据预测,9是无毒和无过敏的 (LD50 = 3,000 mg/kg).
- 9对所有目标蛋白质表现出强烈的结合亲和力:VEGFR2 (-10.90),AKT1 (-10.56),EGFR (-9.82),MAPK8 (-9.64) 和ET-1 (-11.41 kcal/mol).
- 9表现出高水溶性和低药物相互作用风险.
结论:
- 来自Lytechinus variegatus棘的9是一种有前途的候选物,用于治疗动脉样硬化.
- 它的无毒特征和强大的抑制活性表明其具有显著的治疗潜力.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...